

REFERENCES

- Abrams, J. (1197):** Role of endothelial dysfunction in coronary artery disease. *Am J Cardiol*.79 (12B):2-9.
- Aggarwal, M.; Kopia, G.A.; Tio, F. et al., (2004):** Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. *Cardiovasc Res*. 63: 617–624.
- Albert, M.A.; Danielson, E.; Rifai, N. and Ridker, P.M. (2001)::** Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. *JAMA*.; 286: 64–70.
- Aleksander Żurkowski1, Wojciech Wojakowski1 and Tadeusz Dziels (2009):** Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting. *Kardiol Pol*; 67: 623-630.
- Alfonso, F.; Auge, J.M.; Zueco, J. et al. (2005):** Long-term results (three to five years) of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Stenting (RIBS) randomized study. *J Am Coll Cardiol*; 46:756.
- Alfonso, F.; Perez-Vizcayno, M.J.; Hernandez, R. et al (2006):** A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. *J Am Coll Cardiol*; 47:2152–2160.

- Alfonso, F.; Zueco, J.; Cequier, A. et al. (2003):** A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. *J Am Coll Cardiol*; 42:796.
- Almagor, M.; Keren, A. and Banai, S. (2003):** Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. *Am Heart J*;145:248 –53.
- Ambrose J.A. (1989):** Coronary arteriographic analysis and angiographic morphology.*J Am Coll Cardiol.*; 13(7):1492-94.
- Ambrose, J.A.; Winters, S.L.; Arora, R.R. et al. (1986):** Angiographic evolution of coronary artery morphology in unstable angina.*J Am Coll Cardiol.*; 7:472-78.
- Ambrose, J.A.; Winters, S.L.; Stern, A.; et al. (1985):** Angiographic morphology and the pathogenesis of unstable angina pectoris. *J Am Coll Cardiol.*; 5:609-16.
- American Diabetes Association (2006):** Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 29:S43-S48.
- Angeli, V.; Liu, J.; Trogan, E. et al. (2004):** Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. *Proc Natl Acad Sci USA*;101:11779–84.
- Angioi, M.; Abdelmouttaleb, I.; Rodriguez, R.M. et al. (2001):** Increased C-reactive protein levels in patients with in-stent restenosis and its implications. *Am J Cardiol.* 87(10):1189-93.
- Antonio Marzocchi, Francesco Saia, Giancarlo Piovaccari, et al. (2007):** Long-Term Safety and Efficacy of Drug-Eluting

Stents Two-Year Results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) Multicenter Registry. *Circulation*. 115:3181-3188.

Anzai, T.; Yoshikawa, T.; Shiraki, H.; Asakura, Y. et al. (1997): C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. *Circulation*. 96(3):778-84.

Aoki, J.; Abizaid, A.C.; Serruys, P.W. et al. (2005): Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. *J Am Coll Cardiol*; 46:1670–1676.

Arroyo, L.H. and Lee, R.T. (1999): Mechanisms of plaque rupture: mechanical and biologic interactions. *Cardiovascular Research*. 41(2):369-75.

Assosian, R.K. and Sporn, M.B. (1986): Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. *Journal of cell Biology*. 102: 1217 -1223.

Atkinson, J.B.; Harlan, C.W.; Harlan, G.C. and Virmani, R. (1994): The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. *Hum Pathol*. 25(2):154-59.

- Babapulle, M.N.; Joseph, L.; Bélisle, P. et al. (2004):** A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents. *Lancet*.364:583-91.
- Bakhai, A.; Hill, R.A.; Dundar, Y. et al. (2005):** Percutaneous Transluminal Coronary Angioplasty with Stents Versus Coronary Artery Bypass Grafting for People with Stable Angina or Acute Coronary Syndromes. *Cochrane Database Syst Rev*; (1):CD004588.
- Baroldi, G. (1983):** Diseases of the coronary arteries. In: Silver MD, ed. *Cardiovascular Pathology*. Churchill Livingstone, New York. 317–92.
- Batool Ismail (2005):** Rognostic value of CRP levels immediately after onset of acute myocardial infarction. Thesis submitted for partial fulfillment of master degree in cardiology, under supervision by Prof. Mohamed Tarek Zaki, Prof Sameh Shaheen, Dr Mervat Shafik, Ain Shams University. page 42.
- Bauer, J.; Ganter, U.; Geiger, T. et al., (1988):** Regulation of interleukin expression in cultured human blood monocytes and monocyte derived macrophages. *Blood*. 72: 1134-1140.
- Bennett, M.R. (2003):** In-stent restenosis: pathology and implications for the development of drug-eluting stents. *Heart*. 89:218–24.
- Best, P.J.; Lennon, R.; Ting, H.H. et al., (2002):** The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. *J Am Coll Cardiol*. 39:1113.

- Bhargava, Karthikeyan, Ganesan, et al., (2003):** New approaches to preventing restenosis. *BMJ*.327: 274-279.
- Bhatia, V.; Bhatia, R. and Dhindsa, M. (2004):** Drug-eluting stents: new era and new concerns. *Postgrad Med J*.80:13–18.
- Black Steven, Kushner Irving, and David Samols (2004):** C-reactive Protein: A Mini-Review. *The Journal of Biological Chemistry*. 279:48487-90.
- Blake, G.J. and Ridker, P.M. (2003):** C-reactive protein and other inflammatory risk markers in acute coronary syndromes *J Am Coll Cardiol*.41(4S):37S-42S.
- Blankenhorn D.H. and Curry P.J. (1982):** The accuracy of arteriography and ultrasound imaging for atherosclerosis measurement: a review. *Arch Pathol Lab Med*. 106:483-89.
- Brara, S.; Prabhtej, Mehran Moussavian, Mark A. Grise (2003):** Pilot Trial of Oral Rapamycin for Recalcitrant Restenosis *Circulation*.107:1722-1724.
- Braun, R.C.; Mann, M.J. and Dzau, V.J. (1998):** Cell cycle progression: new therapeutic target for vascular proliferative disease. *Circulation*. 98:82–89.
- Brook, R.D.; Brook, J.R. and Rajagopalan, S. (2003):** Air pollution: the "Heart" of the problem. *Current Hypertension Reports*.5:32-9.
- Buellesfeld, L. and Grube, E. (2004):** ABT-578-eluting stents the promising successor of sirolimus- and paclitaxel-eluting stent concepts *Herz*;29:167–70.

- Buffon, A.; Liuzzo, G.; Biasucci, L.M. et al., (1999):** Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. *J Am Coll Cardiol.* 34:1512–21.
- Burgos, V.; Torre-Hernandez, J.M.; Sainz-Laso, F. et al., (2005):** Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents, *Am. J. Cardiol.* 95, 748.
- Carlsson, J.; Stefan, K.; James, Johan Lindbäck, et al., (2009):** Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On-and Off-Label Criteria *J. Am. Coll. Cardiol.* 53:1389-1398.
- Carter, A.J.(2004):** TOR of the cell cycle Are there important implications for diabetics in the era of the drug-eluting stent *Catheter Cardiovasc Interv.* 61:233–236.
- Castagna, M.T.; Mintz, G.S.; Leiboff, B.O. et al., (2001):** The contribution of "mechanical" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. *Am Heart J.* 142:970.
- Cedric Delhaye, Gabriel Maluenda, Kohei Wakabayashi, et al. (2010):** Long-Term Prognostic Value of Preprocedural C-Reactive Protein After Drug-Eluting Stent Implantation, *Am J Cardiol.* 105:826 – 832.
- Cermak, J.; Key, N.S.; Bach, R.R.; Balla J. et al., (1993):** C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. *Blood.* 82:513–20.

- Chen, J.; Chen, J.L.; Yang, Y.J.; et al., (2008):** Drug-eluting stents for the treatment of ostial coronary lesions: comparison sirolimus-eluting stent with paclitaxel-eluting stent. *Coron Artery Dis.* 19: 507-511.
- Chen, M.S.; John, J.M.; Chew, D.P.; et al., (2006):** Bare metal stent restenosis is not a benign clinical entity. *Am Heart J.* 151:1260.
- Chenillot, O.; Henny, J.; Steinmetz, J.; et al., (2000):** High sensitivity C-reactive protein: biological variations and reference limits. *Clin Chem Lab Med.* 38:1003-11.
- Cipollone, F.; Marini, M.; Fazia, M.; et al., (2002):** Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. *Arterioscler Thromb Vasc Biol.* Mar;21(3):327-34.
- Colombo, A.; Orlic, D.; Stankovic, G.; et al., (2003):** Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. *Circulation.* 107:2178–2180.
- Cosgrave, J.; Melzi, G.; Biondi-Zoccai, G.G.; et al., (2006)** Drug-eluting stent restenosis the pattern predicts the outcome. *J Am Coll Cardiol.* 47:2399.
- Curfman, G.D. (2002):** Sirolimus-eluting coronary stents. *N Engl J Med.* 346:1770–1771.
- Cushman, M.; Legault, C.; Barrett-Connor E.; et al., (1999):** Effect of postmenopausal hormones on inflammation-sensitive proteins:

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. *Circulation*.100:717–22.

Cutlip, D.E.; Chauhan, M.S.; Baim, D.S. et al. (2002): Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. *J Am Coll Cardiol*. 40:2082.

Cutlip, D.E.; Windecker, S.; Mehran, R. et al., (2007): Clinical end points in coronary stent trials: a case for standard-ized definitions. *Circulation*.115:2344–51.

Danenberg, H.D.; Szalai, A.J.; Swaminathan, R.V. et al., (2003): Increased thrombosis after arterial injury in human C-reactive proteintransgenic mice. *Circulation*.108(5):512–15.

Dangas G (2001): Restenosis. In *Manual of Interventional Cardiology*. Edited by Freed MS, Safian RD. Royal Oak: Physician's Press; 439–466.

Davies M.J. (1996): Stability and instability: Two faces of coronary atherosclerosis. *Circulation*. 49:2013–20.

Davies, M.J. and Thomas, A. (1984): Thrombosis and acute coronary lesions in sudden cardiac ischaemic death. *N Engl J Med*. 310: 37.

Dibra, A.; Ndrepepa, G.; Mehilli, J.; et al., (2005): A. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. *Am J Cardiol*. 95:1238–1240.

Drachman, D.E.; Edelman, E.R.; Seifert, P. et al., (2000): Neointimal thickening after stent delivery of paclitaxel: change in

composition and arrest of growth over six months. J Am Coll Cardiol. 36 (7): 2325-32.

Du, X.; Kang, J.P.; Wu, J.H. et al., (2010): Elevated high sensitive C-reactive protein and apelin levels after percutaneous coronary intervention and drug-eluting stent implantation. J Zhejiang Univ Sci B. Aug;11(8):548-52.

Ellis, S.; Alderman, E.L.; Cain, K., et al., (1989): Morphology of left anterior descending coronary territory lesions as a predictor of anterior myocardial infarction: a CASS Registry Study. J Am Coll Cardiol. 13:1481-91.

Ellis, S.G.; O'Shaughnessy, C.D.; Martin, S.L. et al., (2008): Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart J.29:1625.

Ellis, S.G.; Vandormael, M.G.; Cowley, M.J. et al., (1990): Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation; 82:1193.

Emmanouil, Z.; Pablo, A. and Ramón Arroyo, E. (2004): Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris. Circulation. 110:1747-53.

Engler, M.M.; Engler, M.B.; Malloy, M.J. et al., (2003): Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 108:1059-63.

- Eric J. Topol (2005):** Acute Coronary Syndromes (textbook).The Cleveland Clinic Foundation, Cleveland, U.S.A.:8-9.
- Eric, J. Topol (2002):** Textbook of cardiovascular medicine. CD. Lippincott Williams and Wilkins. 2nd edition.
- Falk E. (1985):** Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death—autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.Circulation.71:699-708.
- Falk, E.; Shah, P.K. and Fuster, V. (1995):** Coronary plaque disruption. Circulation.49: 657–71.
- Fang, C.H.; Jiang, H.; Huang, C.X. et al.(2004):** Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal artery stenosis. Clin Chim Acta; 350: 115-121.
- Farb, A.; Burke, A.P.; Tang, A.L. et al., (1996):** Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation. 93:1354-63.
- Farb, A.; Heller, P.F.; Shroff, S.; et al., (2001):** Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 104:473–479.
- FDA Guidance for Industry and FDA Staff (2005):** Review Criteria for Assessment of C Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Protein

(cCRP) Assays. Available at <http://www.fda.gov/cdrh/oivd/guidance/1246.html>. Document, issued on: September 22.

Feres, F.; Munoz, J.; Abizaid, A.; et al. (2005): Angiographic and intravascular ultrasound findings of the late catch-up phenomenon after introcoronary beta-radiation for the treatment of in-stent restenosis. *J Invasive Cardiol.* 17:473–477.

Fischman, D.L.; Leon, M.B.; Baim, D.S.; et al., (1994): A randomized comparison of coronary–stent placement and balloon angioplasty in the treatment of coronary artery disease. *N Engl J Med*; 331:496.

Fong, Y.; Moldawer, I.L.; Shiers, G.T. et al., (1990): The biologic characteristics of cytokines and their implication in surgical injury. *Surg Gynecol Obstet* 170: 363-378.

Formica, R.N. Jr, Lorber, K.M. and Friedman, A.L. (2004): The evolving experience using everolimus in clinical transplantation. *Transplant Proc.* 36 (2 suppl):S495–9.

Froun Berger, P.; Pfeifler, M.; Cremer, P. et al., (1998): Validation of an automated enzyme immunoassay for interleukin 6 for routine clinical use. *Clin Chem Lab Med*; 36(10):797 -801.

Fukuda, D.; Shimada, K.; Tanaka, A. et al., (2004): Circulating monocytes and in-stent neointima after coronary stent implantation. *J Am Coll Cardiol.*43:18–23.

- Fuster, V.; Badimon, L.; Cohen, M. et al., (1988):** Insights into the pathogenesis of acute ischemic syndromes. *Circulation*. 77:1213-20.
- Fuster, V.; Frye, R.L.; Kennedy, M.A. et al., (1979):** The role of collateral circulation in the various coronary syndromes. *Circulation*. 59:1137-44.
- Galis Z.S., Sukhova, G.K.; Lark, M.W. and Libby, P. (1994):** Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. *J Clin Invest*. 94(6):2493-503.
- Galis, Z.S.; Muszynski, M.; Sukhova, G.K. et al., (1995):** Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. *Ann NY Acad Sci*. 748:501–507.
- Gallo, R.; Padurean, A.; Chesebro, J.H. et al., (1998):** Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. *Circulation*, 99:2164–2170.
- Gao Run-lin, X.U. Bo, Chen Ji-lin, et al., (2009):** Two-year clinical outcomes following elective drug-eluting versus bare-metal stent implantation: results from a large single-center database *Chinese Medical Journal*. 22(191):2261-2267.
- Garg, S.; Smith, K.; Torguson, R. et al., (2007):** Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. *Catheter Cardiovasc Interv*; 70:9.

- Gaspardone, A.; Crea, F.; Versaci, F. et al., (1998):** Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. *Am J Cardiol.* 82:515–518.
- Gaspardone, A.; Francesco, V.; Fabrizio, T. et al., (2006):** C-Reactive Protein, Clinical Outcome, and Restenosis Rates After Implantation of Different Drug-Eluting Stents *Am J Cardiol.* 97,(9), 1311-1316.
- Gaudino, M.; Cellini, C.; Pragliola, C. et al., (2005):** Arterial versus venous bypass grafts in patients with in-stent restenosis. *Circulation*; 112:I265.
- George Dangas, Solinas, E.; Dangas, G. et al., (2008):** Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. *Am J. Cardiol*;102:311–315.
- Gershlick, A.H.; Abizaid, A.; Guagliumi, et al., (2005):** Real world use of sirolimus eluting stents in saphenous vein graft disease: data from the e-cypher registry. *Heart.* 91 (Supplement I):A5, May.
- Glagov, S.; Weisenberg, E.; Zarins, C.K. et al., (1987):** Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med.* 316:1371-75.
- Gogo, P.B.; Schneider, D.J.; Watkins, M.W.; et al., (2005):** Systemic inflammation after drug-eluting stent placement. *Journal of Thrombosis and Thrombolysis*, 19(2):87-92.

- Goldstein, R.A.; Kirkeeide, R.L.; Demer, L.L. et al., (1987):** Relation between geometric dimensions of coronary artery stenoses and myocardial perfusion reserve in man. J Clin Invest.79(5):1473-78.
- Gomma, A.H.; Hirschfield, G.M.; Gallimore, J.R. et al., (2004):** Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting . American Heart Journal. 147(6):1071-1077.
- Gotlieb, A.I. and Havenith, M.G. (1991):** Atherosclerosis lesions and pathogenesis. In: Silver MD, ed. Cardiovascular Pathology, 2nd edition. Churchill Livingstone, New York. 225–65.
- Gottsauer-Wolf, M.; Zasmata, G.; Hornykewycz, S. et al., (2000):** Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 21: 1152 –58.
- GUSTO Angiographic Investigators (1993):** The effects of TPA, streptokinase or both on coronary artery patency, ventricular function and survival after AMI. NEJM ; 329:1615.
- Hack, C.E.; De Groot, E.R.; Felt-Bersma, R.J. et al., (1989):** Increased plasma level of inter-leukin and in Sepsis.Blood. 74: 1704 - 1710.
- Haffner, S.M.; Greenberg, A.S.; Weston, W.M. et al., (2002):** Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation.106(6):679–84.

- Halkin, A. and Stone, G.W. (2004):** Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. *Journal of Interventional Cardiology*. 17(5): 271-82.
- Hansson, G.K. (2005):** Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med*;352:1685–95.
- Hao, H.; Yutani, C. and Imakita, M. (1993):** Histopathological analysis on plaque disruption of coronary arteries in acute myocardial infarction. *J. Cardiol*. 49 4: 105.
- Haraguchi, G.; Pruitt, S.; Brodeur, A. et al., (2006):** Increased expression of eNOS by Endeavor zotarolimus-eluting stents compared to other DES in porcine coronary artery implants. *Am J Cardiol*. 98: 32–33.
- Hausleiter, J.; Kastrati, A.; Mehilli, J. et al., (2002):** Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. *J Am Coll Cardiol*. 40: 882–889.
- Haverkate, F.; Thompson, S.G.; Pyke, S.D.; et al., (1997):** Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. *Lancet*. 349(9050):462-66.
- Hermiller, J.B.; Raizner, A.; Cannon, L. et al., (2005):** Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. *J Am Coll Cardiol*. 45:1172–1179.

- Hernandez, J.M.; Sainz-Laso, F.; Burgos, V. et al., (2005):** Comparison of C-reactive protein levels after coronary stenting with bare metal versus sirolimus-eluting stents. *Am J Cardiol.* 15;95(6):748-51.
- Hoffmann, R. and Mintz, G.S. (2000):** Coronary in-stent restenosis - predictors, treatment and prevention. *Eur Heart J.* 21:1739.
- Hoffmann, R.; Mintz, G.S.; Dussaillant, G.R.; et al., (1996):** Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. *Circulation*, Sep 15;94(6):1247-54.
- Hwang, C.W.; Wu, D. and Edelman, E.R. (2001):** Physiological transport forces govern drug distribution for stent-based delivery. *Circulation.* 104:600–605.
- Ingham, E. (2000):** Cytokines In: Recent advances in anaesthesia and analgesia, edited by Adams AP and Cashman JN, Vol 21, Chapter 2 pp 17-39.
- Jeong, W.K.; Jeong, M.H.; Kim, K.H. et al., (2003):** An elevated value of C-reactive protein is the only predictive factor of restenosis after percutaneous coronary intervention. *Korean J. Intern. Med.* 2003; 18: 154–60.
- John Beilby (2003):** Summary statement from a workshop on markers of inflammation and cardiovascular disease: Applications to clinical and public health practice *Circulation.* 107:499-11.
- Johnson, J.M.; Kennelly, M.M.; Decesare, D. et al., (1985):** Natural history of asymptomatic carotid plaque. *Arch Surg.* 120:1010-12.

- Karaca, I.; Aydin, K.; Yavuzkir, M. et al., (2005):** A Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. *J Int Med Res*; 33: 389-96.
- Karthikeyan, G. and Bhargava, B. (2004):** Prevention of restenosis after coronary angioplasty. *Curr Opin Cardiol*.19:500–9.
- Kastrati, A.; Dibra, A.; Mehilli, J. et al., (2006):** Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. *Circulation* ; 113:2293–2300.
- Kastrati, A.; Mehilli, J.; von Beckerath, N. et al., (2005):** Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA.*; 293:165.
- Kastrati, A.; Schomig, A.; Elezi, S. et al., (1998):** Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. *Circulation*; 97:2396.
- Kastrati, A.; Schomig, A.; Elezi, S.; et al., (1999):** Prognostic Value of the Modified American College of Cardiology/American Heart Association Stenosis Morphology Classification for Long-Term Angiographic and Clinical Outcome After Coronary Stent Placement. *Circulation*. 100:1285.
- Kereiakes, D.J.; Cox, D.A.; Hermiller, J.B. et al., (2003):** Usefulness of a cobalt chromium coronary stent alloy. *Am J Cardiol.*, 92:463–466.

- Kim, J.Y.; Ko, Y.G.; Shim, C.Y. et al., (2005):** Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. *Am J Cardiol.* 96:1384–1388.
- Kimura, T.; Yokoi, H.; Nakagawa, Y.; et al., (1996):** Three-year follow-up after implantation of metallic coronary stents. *N Engl J Med.* 334:561–566.
- Klitkou, J.; Jensen, L.O.; Hansen, H.S. and Thayssen, P. (2007):** High sensitive C-reactive protein and interleukin 6 are not related to neointimal hyperplasia in paclitaxel eluting stents or bare metal stents. An intravascular ultrasound study. *Int J Cardiol.*; 119:114–6.
- Kohase, M.; May, I.T.; Tamm, I. et al., (1987):** A Cytokine network in human diploid fibroblasts. Interactions of B interferons, Tumour necrosis factor, Platelet derived growth factor and interleukin 1. *Mol, Cell Biol.* 7: 278 - 280.
- Kolodgie, F.D.; John, M.; Khurana, C. et al., (2002):** Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. *Circulation*; 106 (10): 1195-8.
- Koster, R.; Vieluf, D.; Kiehn, M.; et al., (2000):** Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. *Lancet*; 356:1895.
- Kozinski, M.; Krzewina-Kowalska, A.; Kubica, J. et al., (2005):** Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent

restenosis comparison with stable and unstable angina. Inflamm Res.54(5):187-93.

Kragel, A.H.; Gertz, S.D. and Roberts W.C. (1991): Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction. J Am Coll Cardiol.18:801-808.

Kralisz, P.; Kemon, H. and Dobrzycki, S. (2006): Changes in C-reactive protein levels following coronary stent implantation depend on the extent of periprocedural arterial injury. Kardiologia Pol. 64: 364-71.

Kuller, L.H.; Tracy, R.P.; Shaten, J. and Meilahn, E.N. (1996): Relation of C-reactive protein and coronary heart-disease in the MRFIT nested case control study. Am. J. Epidemiol. 144:537-47.

Lang, R.M.; Bierig, M.; Devereux, R.B. et al., (2005): Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-63.

Lederer, J.A. and Abbas, A.K. (1993): Cytokines in specific Immune Responses. In: Samter Immune-logic Diseases, Edited by Frank MM, Austen KF, Claman HN, Unanue ER. Fifth edition, Volim I, Chapter 10, pp 129-141.

- Lemos, P.A.; Hoyer, A.; Goehart, D. et al., (2004):** Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. *Circulation*. 109:1366.
- Lendon, C.L.; Davies, M.J.; Born, G.V.R. et al., (1991):** Atherosclerotic plaque caps are locally weakened when macrophages density is increased. *Atherosclerosis*. 49: 87–90.
- Leon, B.F.; Moses, J.; Holmes, D.R. et al., (2006):** Long-term benefit of Cypher sirolimus eluting coronary stents four year follow-up of the SIRIUS study. Paper presented at: Annual Scientific Sessions of the American College of Cardiology; March 11–14, Atlanta, Ga.
- Levin, A.D.; Vukmirovic, N.; Hwang, C.W. et al., (2004):** Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. *Proc Natl Acad Sci U S A*. 101:9463–9467.
- Levin, D.C. and Fallon, J.T. (1982):** Significance of the angiographic morphology of localized coronary stenoses: histopathologic correlations. *Circulation*. 66:316-20.
- Lewis, A.L.; Tolhurst, L.A. and Stratford, P.W. (2002):** Analysis of phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. *Biomaterials*. 23:1697–1706.
- Li Jian-jun (2008):** Inflammatory response, drug-eluting stent and restenosis *Chin Med J*.121(6):566-572.

- Li, H.; Cybulsky, M.I.; Gimbrone, M.A. Jr., et al., (1993):** An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. *Arterioscler Thromb.* 13(2):197–204.
- Li, J.J.; Qin, X.W.; Yang, X.C. et al., (2008):** Randomized comparison of early inflammatory response after sirolimus-eluting stent versus bare metal stent implantation in native coronary lesions. *Clin Chim Acta.* 396: 38-42.
- Libby, P. (1995):** Molecular bases of the acute coronary syndromes. *Circulation*; 49: 2844–50.
- Libby, P. (2002):** Inflammation in atherosclerosis. *Nature.* 420(6917):868–74.
- Libby, P. and Ridker, P.M. (1999):** Novel inflammatory markers of coronary risk: Theory versus practice. *Circulation.* 100:1148–50.
- Libby, P.; Ridker, P.M. and Maseri, A. (2002):** Inflammation and atherosclerosis. *Circulation.* 105:1135–43.
- Libby, P.; Warner, S.J. and Friedman, G.B. (1988):** Interleukin 1 a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. *J Clin Invest.* 81(2):487-98.
- Luigi, M.; Biasucci, Giovanna Liuzzo, Dominik J.A. et al., (2000):** Inflammation and Acute Coronary Syndromes. *Herz.*; 25 (2): 108-12.

- Luna C.M. (2004):** C-reactive protein in pneumonia: let me try again (editorial). *Chest*. 125: 1192–95.
- Mackay, J. and Mensah, G.A. (2008):** The atlas of heart disease and stroke, Deaths from coronary heart disease 2002. Available at: [http:// www .wgho.int/cardiovascular_diseases /resources /atlas/en/index.html](http://www.wgho.int/cardiovascular_diseases/resources/atlas/en/index.html). Accessed June 12.
- Madsen, T.; Skou, H.A.; Hansen, V.E. et al., (2001):** C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. *Am J Cardiology*. 88:1139-42.
- Mann, J. and Davies, M,J. (1999):** Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. *Heart*. 82:265–8.
- Marc, S.; Sabatine, Morrow D.A.; Jablonski, K.A. et al., (2007):** Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. *Circulation*. 115:1528-36.
- Mark, A. and Crowther (2005):** Pathogenesis of Atherosclerosis (textbook). American society of heamatology education programe book.
- Marx, S. and Marks, A. (2001):** Bench to bedside: the development of rapamycin and its application to stent restenosis. *Circulation*. 104:852–855.

- Maser, A. and Cianflone, D. (2002):** Inflammation in acute coronary syndromes. European Heart Journal Supplements. 4 (Supp B), B8–B13.
- Mauri, L.; O'Malley, A.J.; Cutlip, D.E. et al., (2004):** Effects of stent length and lesion length on coronary restenosis. Am J Cardiol 93:1340.
- May Moussa D. (2003):** C-reactive proteins level after coronary stent deployment in patients with stable coronary artery disease. Thesis submitted for partial fulfillment of master degree in cardiology .under supervision of professor Waffa A, assistant professor Mohammed Z., Dr Hossam EL-Din . Cairo University.64.
- Mehran, R.; Dangas, G.; Abizaid, A.S. et al., (1999):** Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation100:1872–1878.
- Meredith, I.T.; Ormiston, J.; Whitbourn, R. et al., (2004):** Endeavor I, ‘first in man’, safety and efficacy study, 12 months clinical, angiographin and intravascular ultrasound results . Circulation.110: III-563-4.
- Migliorini, A.; Shehu, M.; Carrabba, N. et al., (2005):** Predictors of outcome after sirolimus-eluting stent implantation for complex in-stent restenosis. Am J Cardiol. 96:1110.
- Milazzo, D.; Biasucci, L.; Luciani, N. et al., (1999):** Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol. 84:459–61.

- Mintz, G.S.; Popma, J.J.; Pichard, A.D. et al., (1996):** Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. *Circulation*, Jul 1;94(1):35-43.
- Mishkel, G.J.; Moore, A.L.; Markwell, S. et al., (2007):** Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. *J Am Coll Cardiol.* 49:181.
- Mitra, A.K. and Agrawal, D.K. (2006):** In stent restenosis: bane of the stent era. *J Clin Pathol.*; 59(3):232-9.
- Moreno, P.R. and Fuster, V. (2004):** The year in atherothrombosis. *J Am Coll Cardiol.* 44(11):2099–10.
- Moreno, P.R.; Falk, E.; Palacios, I.F. et al., (1994):** Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. *Circulation.* 90(2):775-78.
- Morice, M.C.; Serruys, P.W.; Sousa, J.E. et al., (2002):** Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions: a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med.*346:1773–1780.
- Morrow, D. and Ridker, P. (2000):** C-reactive protein, inflammation, and coronary risk. *Medical Clinics of North America.* 84(1); 149-61.
- Morrow, D.A.; de Lemos, J.A.; Sabatine, M.S. et al., (2006):** Clinical relevance of C-reactive protein during follow-up of patients

with acute coronary syndromes in the Aggrastat-to-Zocor Trial. *Circulation*.114:281–288.

Morrow, D.A.; Gersh, B.J. and Braunwald, E. (2005): Chronic coronary artery disease. In: Braunwald's Heart Disease, 7th ed. Philadelphia: Saunders. 1281-1308.

Moses, J.W.; Leon, M.B.; Popma, J.J. et al., (2003): Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med*. 349:1315.

Moshage, H.J.; Roelofs, H.M.; van Pelt, J.F. et al., (1988): The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. *Biochem Biophys Res Commun*. 155(1):112-17.

Moussa, I.D.; Moses, J.W.; Kuntz, R.E. et al., (2006): The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial). *Am J Cardiol*. 97:1582.

Moustapha, A.; Assali, A.R.; Sdringola, S. et al., (2001): Percutaneous and surgical interventions for in-stent restenosis: Long-term outcomes and effect of diabetes mellitus. *J Am Coll Cardiol*; 37:1877.

Mukherjee, D. and Moliterno, D.J. (2006): Brachytherapy for in-stent restenosis: a distant second choice to drug-eluting stent placement. *JAMA*; 295:1307.

- Neumann, F.J.; Desmet, W.; Grube, E. et al., (2005):** Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. *Circulation*; 111:2107.
- Nick, E.J.; West, Peter N. et al., (2004):** Clinical and Angiographic Predictors of Restenosis After Stent Deployment in Diabetic Patients *Circulation*.109:867-873.
- Nihat Ozer, Burak Tangurek, Fatih Firat et al., (2008):** Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention *Heart vessels*.23:75 – 82.
- Nirav, J.; Mehta and Ijaz A. Khan (2002):** Cardiology's 10 Greatest Discoveries of the 20th Century. *Tex Heart Inst J*. 29(3): 164–71.
- Nissen, S.E. and Yock, P. (2001):** Intravascular ultrasound: novel pathophysiological insights and current clinical applications. *Circulation*. 103:604–16.
- Olivier Gach, Victor Legrand and Yves Biessaux (2007):** Long-Term Prognostic Significance of High-Sensitivity C-Reactive Before and After Coronary Angioplasty in Patients With Stable Angina Pectoris.*Am J Cardiol*. 1;99(1):31-5.
- Oltrona, L.; Eisenberg, P.R.; Lasala, J.M. et al., (1996):** Winters KJ. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. *Circulation*. 94:2064 –71.

- Ozer, N.; Tangurek, B.; Firat, F. et al., (2008):** Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention. *Heart Vessels*. 23(2):75-82.
- Pache, J.; Kastrati, A.; Mehilli, J. et al., (2003):** Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. *J Am Coll Cardiol*; 41:1283.
- Park, D.W.; Lee, C.W.; Yun, S.C. et al., (2007):** Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. *Heart*. 93:1087–1092.
- Patel, V.B.; Robbins, M.A. and Topol E.J. (2001):** C reactive protein: a golden marker of inflammation and coronary artery disease. *Cleveland clinic journal of medicine*. 521: 6, 68.
- Patrick, I.; Kay and Manel Sabaté (2004):** Cardiac Catheterization and Percutaneous Interventions (Textbook). Taylor & Francis Group(London). page 521.
- Piatti, P.M.; Di Mario, C.; Monti, L.D. et al., (2003):** Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. *Circulation* 108: 2074-81.
- Pietersma, A.; Marcel Kofflard, L. Elly A. et al., (1995):** Late Lumen Loss After Coronary Angioplasty Is Associated With the Activation Status of Circulating Phagocytes Before Treatment. *Circulation*. 91:1320-1325.

- Probal Roy, Teruo Okabe, Tina L. et al., (2007):** Correlates of Clinical Restenosis Following Intracoronary Implantation of Drug-Eluting Stent. *Am J Coll Cardiol.*40:965–969.
- Rainer Hoffmann, Gary S.; Mintz, Gaston R.; Dussaillant et al., (1996):** Patterns and Mechanisms of In-Stent Restenosis: A Serial Intravascular Ultrasound Study. *Circulation.* 94: 1247-54.
- Rajagopal, V.; Gurm, H.S.; Bhatt, D.L. et al., (2004):** Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. *Am J Cardiol.* 94: 190–2.
- Ranade, S.V.; Miller, K.M.; Richard, R.E. et al., (2004):** Physical characterization of controlled release of paclitaxel from the Taxus Express drug-eluting stent. *J Biomed Mater Res.* 71A:625–34.
- Regar, E.; Serruys, P.W.; Bode, C. et al., (2002):** Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. *Circulation*106:1949-1956.
- Ridker, P.M. (2001):** High-Sensitivity C-Reactive Protein: Potential Adjunct for Global Risk Assessment in the Primary Prevention of Cardiovascular Disease. *Circulation.* 103:1813.
- Ridker, P.M. (2003):** Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention. *Circulation.*; 107:363.

- Ridker, P.M. (2003):** High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. *The American Journal of Cardiology*.92(2): 17-22.
- Ridker, P.M. (2008):** The Time for Cardiovascular Inflammation Reduction Trials Has Arrived: How Low to Go for hsCRP? *Arteriosclerosis, Thrombosis, and Vascular Biology*. 28:1222.
- Ridker, P.M.; Buring J.E., Shih J., et al. (1998):** Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. *Circulation*. 98:731-33.
- Ridker, P.M.; Cushman, M.; Stampfer, M.J. et al., (1997):** Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med*. 336:973–79.
- Ridker, P.M.; Cushman, M.; Stampfer, M.J. et al., (1998):** Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. *Circulation*. 97:425–28.
- Ridker, P.M.; Danielson, E.; Fonseca, F.A. et al., (2008):** Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 359(21):2195-207.
- Ridker, P.M.; Hennekens, C.H.; Buring, J.E. and Rifai, N. (2000):** C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N. Engl. J. Med*. 342:836-43.
- Ridker, P.M.; Hennekens, C.H.; Roitman, J.B. et al., (1998):** Plasma concentration of soluble intercellular adhesion molecule 1 and

risks of future myocardial infarction in apparently healthy men. *Lancet*. 351:88.

Ridker, P.M.; Rifai, N.; Clearfield, M. et al., (2001): Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med*. 344:1959–65.

Ridker, P.M.; Rifai, N.; Pfeffer, M.A. et al., (1998): Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. *Circulation*. 98:839–44.

Ridker, P.M.; Rifai, N.; Pfeffer, M.A. et al., (1999): Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. *Circulation*. 100:230–35.

Ridker, P.M.; Rifai, N.; Rose, L.; Buring, J.E. and Cook N.R. (2002): Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med*. 347: 1557–65.

Ridker, P.M.; Stampfer, M.J. and Rifai, N. (2001): Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. *JAMA*. 285(19):2481–85.

Robbins and Cotran (2005): *Pathologic Basis of Disease*. 7th ed. Philadelphia, Pa: Elsevier Saunders 525.

- Robert, A.; Rourke, O.; Ross, A. et al., (2008):** Optimal Medical Therapy Is a Proven Option for Chronic Stable Angina .J Am Coll Cardiol. 52:905-907.
- Roiron, C.; Sanchez, P.; Bouzamondo, A. et al., (2006):** Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart. 92:641.
- Roivanen, M.; Viik-Kajander, M.; Paluso, T. et al., (2000):** Infections, inflammation, and the risk of coronary heart disease. Circulation. 101: 252–57.
- Rosalki S.B. (2001):**C-reactive protein. Int J Clin Pract. 55(4):269-70.
- Ross, R. (1986):** The pathogenesis of atherosclerosis: An update. N. Engl. J. Med. 49: 488–500.
- Sabate, M.; Costa, M.A.; Kozuma, K. et al., (2000):** Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy. J Am Coll Cardiol.36:1536–1541.
- Saleh, N.; Svane, B.; Jensen, J. et al., (2005):** Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 concentrations after percutaneous coronary intervention in patients with stable angina pectoris. Am Heart J.149:876–82.
- Sardella, G.; Mariani, P.; Alessander, M.; et al., (2006):** Early elevation of interleukin-1beta and interleukin-6 levels after bare or drug-eluting stent implantation in patients with stable angina. Thromb Res; 117: 659-664.

- Savage, M.P.; Fischman, D.L.; Rake, R.; et al., (1996):** for the Palmaz-Schatz Stent Investigators. Interprocedural interval as a predictor of stent restenosis after previous coronary angioplasty. *Am J Cardiol.* 78:683.
- Scanlon, P.J.; Faxon, D.P.; Audet, A.M.; et al., (1999):** ACC/AHA guidelines for coronary angiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. *J Am Coll Cardiol.* 33:1756.
- Scheller, B.; Grandt, A.; Wnendt, S. et al., (2005):** Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. *Z Kardiol.*94:445–452.
- Scheller, B.; Hehrlein, C.; Bocksch, W. et al., (2006):** Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *N Engl J Med.* 355:2113.
- Schoenhagen, P.; Ziada, K.M.; Vince, D.G. et al., (2002):** Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. *J Am Coll Cardiol.* Aug;38(2):297-306.
- Schonbeck, U. and Libby, P. (2004):** Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. *Circulation.* 109(21 Suppl 1): II18–II26.
- Segev, A.; Kassam, S.; Buller, C.E.; et al., (2004):** Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not

predict late coronary angiographic restenosis after elective stenting. *Eur Heart J*;25:1029–1035.

Serrano, C.V.; Ramires, J.A.; Venturinelli, M. et al., (1997): Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. *J Am Coll Cardiol.* 29:1276-83.

Serruys, P.; Piek, J.J.; Neumann, F.J. et al., (2005): A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. *Euro Intervention.* 1:58–65.

Serruys, P.W. and Kutryk, M.J. (1996): The state of the stent: current practices, controversies, and future trends. *Am J Cardiol.* 78(3A):4-7.

Serruys, P.W.; Kay, I.P.; Disco, C. et al., (1999): Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BELgian NETHERlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. *J Am Coll Cardiol.* 34:1067.

Serruys, P.W.; Kutryk, M.J. and Ong, A.T. (2006): Coronary-artery stents. *N Engl J Med.* 354:483–495.

Sheeran, P. and Hall, G.M. (1997): Cytokines in anesthesia. *British Journal of anesthesia,* 75: 201 - 218.

- Silber, S.; Albertsson, P.; Aviles, F.F. et al., (2005):** Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J; 26:804.
- Singh, M.; Gersh, B.J.; McClelland, R.L. et al. (2004):** Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation. 109:2727.
- Sketch, M.H. Jr, Ball, M.; Rutherford, B.; et al., (2005): for the Driver Investigators.** Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol.95:8–12.
- Smith, S.C.; Jr, Feldman, T.E.; Hirshfeld, J.W. Jr, et al., (2006):** ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 47:e1.
- Sorokin, A.; Brown, J.L. and Thompson, P.D. (2007):** Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 194:293.
- Sousa, J.E.; Sousa, A.G.; Costa, M.A.; et al., (2003):** Use of rapamycin-impregnated stents in coronary arteries. Transplant Proc; 35:165S –70S.

- Stary, H.C.; Blankenhorn, D.H.; Chandler, A.B. et al., (1992):*** A definition of the intima of human arteries and of its atherosclerosis-prone regions: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation.*; 49: 391-405.
- Steven, B. Feinstein (2008):*** Non-invasive Surrogate Markers of Atherosclerosis (Textbook) . Informa Healthcare publication (UK). 99-100.
- Steven, E. Nissen (2009):*** The Jupiter Trial: Key Findings, Controversies, and Implications. *Current Cardiology Reports.* 11:81–82.
- Stone, G.W.; Ellis, S.G.; Cannon, L.; et al., (2005):*** Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. *JAMA.* 294:1215–1223.
- Stone, G.W.; Ellis, S.G.; Cox, D.A. et al., (2004):*** One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial, *Circulation.*109, 1942 .
- Takebayashi, H.; Mintz, G.S.; Carlier, S.G.; et al., (2004):*** Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. *Circulation*110:3430–3434.
- Teirstein, P.S. (2004):*** A chicken in every pot and a drug-eluting stent in every lesion. *Circulation.* 109:1906–1910.

- Terstein, P.S.; Massullo, V.; Popma, J.J. et al., (1997):** A double-blinded randomized trial of catheter-based radiotherapy to inhibit restenosis following coronary stenting. *N Engl J Med* 336:1697.
- Thomas, A.; Pearson, George A.; Mensah, Wayne R.A. et al., (2003):** AHA/CDC Scientific Statement: Markers of Inflammation and Cardiovascular Disease : Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association . *Circulation*. 107:499.
- Thomas, A.C.; Davies, M.J.; Dilly, S.; Dilly, N. and Franc, F. (1986):** Potential errors in the estimation of coronary arterial stenosis from clinical arteriography with reference to the shape of the coronary arterial lumen. *Br Heart J*.55:129-39.
- Thygesen, K.; Alpert, J.S. and White, H.D. (2007):** On behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction; The Universal Definition of Myocardial Infarction. *Circulation*.116:2634-2653.
- Toutouzas, K.; Colombo, A. and Stefanadis, C. (2004):** Inflammation and restenosis after percutaneous coronary interventions. *Eur Heart J*. 25:1679–87.
- Tschoepe, D.; Schultheib, H.B.; Kolarov, P.; et al., (1993):** Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. *Circulation*.88:37-42.
- Unverdorben, M.; Vallbracht, C.; Cremers, B. et al., (2009):** Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the

treatment of coronary in-stent restenosis. *Circulation*. 119:2986.

Vander Wal, A.C.; Becker, A.E.; van der Loos, C.M. et al., (1994): Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of dominant plaque morphology. *Circulation*. 89:36-44.

Venugopal, S.K.; Devaraj, S. and Jialal, I. (2005): Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. *Am J Pathol*. 166:1265–71.

Versaci, F.; Gaspardone, A.; Tomai, F. et al., (1997): A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. *N Engl J Med*. 336:817–22.

Versaci, F.; Gaspardone, A.; Tomai, F. et al., (2000): Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. *Am J Cardiol*. 85:92-95, A8.

Versaci, F.; Gaspardone, A.; Tomai, F. et al., (2002): Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). *J Am Coll Cardiol*. 40:1935-42.

Violaris, A.G.; Thury, A.; Regar, E. et al., (2000): Influence of a history of smoking on short term (six month) clinical and

angiographic outcome after successful coronary angioplasty. Heart.84:299.

Virmani, R. (2006): Safety of Polymer Coating on Drug-Eluting Stents: What You Don't Know Could Kill You. Washington, DC: Transcatheter Cardiovascular Therapeutics; Washington DC.

Virmani, R.; Guagliumi, G.; Farb, A. et al., (2004): Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious. Circulation. 109: 701–705.

Walter, D.H.; Fichtlscherer, S.; Sellwig, M. et al., (2001): Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J. Am. Coll. Cardiol.37:839–46.

Webster, M.S.I.; Chesebro, J.H.; Smoth, H.C.; et al., (1990): Myocardial infarction and coronary artery occlusion: a prospective 5- year angiographic study. J Am Coll Cardiol.15(1):15218A.

Weiss, S.J. (1989): Tissue destruction by neutrophils. N Engl J Med. 320(6):365-76.

Welt, F.G. and Rogers, C. (2002): Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 1;22(11):1769-76.

Wessely, R.; Kastrati, A. and Schömig, A. (2005): Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 143:392–394.

- Whelan, D.M.; van der Giessen, W.J.; Krabbendam, S.C. et al., (2000):** Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. *Heart*.83:338–345.
- Whicher, J.T. and Evans, S.W. (1990):** Cytokines in disease .*J Clinical chemistry*. 36(7): 1269-1281.
- White, C.J. (2005):** Drug-Eluting Stents Advanced Applications for the Management of Coronary Disease. Taylor & Francis. pp.7-11, 15, 19, 22-23, 74.
- Wong, N.D.; Wilson, P.W. and Kannel, W.B. (1991):** Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. *Ann Intern Med*.115:687–93.
- Woolf, N. (1982):** Pathology of Atherosclerosis (Textbook). Butterworth Scientific, London.
- Yasojima, K.; Schwab, C.; McGeer, E.G. and McGeer, P.L. (2001):** Generation of C-reactive protein and complement components in atherosclerotic plaques. *Am J Pathol*.158: 1039–51.
- Yip, H.K.; Hung, W.C.; Yang, C.H. et al., (2005):** Serum concentrations of high-sensitivity C-reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting. *Circ J*. 69: 1202-7.
- Yung-Lung Chen, Hon-Kan Yip, Chien-Jen Chen (2009):** Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease. *Acta Cardiol Sin*.25:1-6.

- Yutani, C.; Imakita, M.; Ishibashi-Ueda, H. et al., (1988):** Localization of lipids and cell population in atheromatous lesion in aorta and its main arterial branches in patients with hypercholesterolemia. In: Yoshida Y, et al., . Role of Blood Flow in Atherogenesis. Springer-Verlag, (Tokyo).25–31.
- Zairis, M.N.; Manousakis, S.J.; Stefanidis, A.S. et al., (2003):** C-reactive protein and rapidly progressive coronary artery disease – is there any relation? Clin Cardiol. 26: 85-90.
- Zarins, C.K.; Weisenberg, E.; Kolettis, G. et al., (1988):** Differential enlargement of artery segments in response to enlarging atherosclerotic plaques. J Vasc Surg. 7:386-94.
- Zimmerman, Donald W. (1997):** A Note on Interpretation of the Paired-Samples t Test". Journal of Educational and Behavioral Statistics. 22 (3): 349–360.